[HTML][HTML] Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment

C Marçais, B Verges, S Charrière… - The Journal of …, 2005 - Am Soc Clin Investig
C Marçais, B Verges, S Charrière, V Pruneta, M Merlin, S Billon, L Perrot, J Drai, A Sassolas…
The Journal of clinical investigation, 2005Am Soc Clin Investig
While type 1 hyperlipidemia is associated with lipoprotein lipase or apoCII deficiencies, the
etiology of type 5 hyperlipidemia remains largely unknown. We explored a new candidate
gene, APOA5, for possible causative mutations in a pedigree of late-onset, vertically
transmitted hyperchylomicronemia. A heterozygous Q139X mutation in APOA5 was present
in both the proband and his affected son but was absent in 200 controls. It was subsequently
found in 2 of 140 cases of hyperchylomicronemia. Haplotype analysis suggested the new …
While type 1 hyperlipidemia is associated with lipoprotein lipase or apoCII deficiencies, the etiology of type 5 hyperlipidemia remains largely unknown. We explored a new candidate gene, APOA5, for possible causative mutations in a pedigree of late-onset, vertically transmitted hyperchylomicronemia. A heterozygous Q139X mutation in APOA5 was present in both the proband and his affected son but was absent in 200 controls. It was subsequently found in 2 of 140 cases of hyperchylomicronemia. Haplotype analysis suggested the new Q139X as a founder mutation. Family studies showed that 5 of 9 total Q139X carriers had hyperchylomicronemia, 1 patient being homozygote. Severe hypertriglyceridemia in 8 heterozygotes was strictly associated with the presence on the second allele of 1 of 2 previously described triglyceride-raising minor APOA5 haplotypes. Furthermore, ultracentrifugation fraction analysis indicated in carriers an altered association of Apoa5 truncated and WT proteins to lipoproteins, whereas in normal plasma, Apoa5 associated with VLDL and HDL/LDL fractions. APOB100 kinetic studies in 3 severely dyslipidemic patients with Q139X revealed a major impairment of VLDL catabolism. Lipoprotein lipase activity and mass were dramatically reduced in dyslipidemic carriers, leading to severe lipolysis defect. Our observations strongly support in humans a role for APOA5 in lipolysis regulation and in familial hyperchylomicronemia.
The Journal of Clinical Investigation